Last edition
News about "Narcolepsy treatment"
Japan Approves Takeda's ORZEYFUL (Oveporexton) for Narcolepsy Type 1
Japan approves ORZEYFUL (oveporexton) as the first and only medicine targeting the underlying cause of narcolepsy type 1, following positive phase 3 results.
Narcolepsy Treatment | 24/08/2026 | By News Bureau | 102
Takeda's Oveporexton Improves Daily Function in Narcolepsy Type 1
Takeda’s phase 3 data show oveporexton improved daily function, cognition, and nighttime sleep in people with narcolepsy type 1. The results support the potential of the first orexin agonist therapy, with regulatory submissions currently under review.
Narcolepsy Treatment | 16/06/2026 | By News Bureau | 116
Suven Life Sciences Announces 3 Poster Presentations on Samelisant
Suven Life Sciences showcases 3 posters on Samelisant (SUVN-G3031), including findings from the global phase 3 AWAKE Narcolepsy Study at SLEEP 2026.
Narcolepsy Treatment | 12/06/2026 | By News Bureau | 201
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy